271 related articles for article (PubMed ID: 9820092)
1. [The effect of weight reduction on compensation in diabetic obese patients with non-insulin dependent diabetes mellitus].
Szabó M
Vnitr Lek; 1998 Mar; 44(3):145-50. PubMed ID: 9820092
[TBL] [Abstract][Full Text] [Related]
2. [The effect of body weight on insulin activity].
Sindelka G; Skrha J; Prázný M; Hilgertová J
Vnitr Lek; 1999 Sep; 45(9):540-4. PubMed ID: 10951879
[TBL] [Abstract][Full Text] [Related]
3. Beta-cell function and mass in type 2 diabetes.
Larsen MO
Dan Med Bull; 2009 Aug; 56(3):153-64. PubMed ID: 19728971
[TBL] [Abstract][Full Text] [Related]
4. Lack of association between the Pro12Ala polymorphism in PPAR-gamma2 gene and body weight changes, insulin resistance and chronic diabetic complications in obese patients with type 2 diabetes.
Stefanski A; Majkowska L; Ciechanowicz A; Frankow M; Safranow K; Parczewski M; Pilarska K
Arch Med Res; 2006 Aug; 37(6):736-43. PubMed ID: 16824933
[TBL] [Abstract][Full Text] [Related]
5. Management of obesity in NIDDM (non-insulin-dependent diabetes mellitus).
Cheah JS
Singapore Med J; 1998 Aug; 39(8):380-4. PubMed ID: 9844503
[TBL] [Abstract][Full Text] [Related]
6. Effect of insulin and energy restriction on the thermic effect of protein in type 2 diabetes mellitus.
Gougeon R
Obes Res; 2001 Apr; 9(4):241-50. PubMed ID: 11331427
[TBL] [Abstract][Full Text] [Related]
7. New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat.
Scheen AJ; Ernest P
Diabetes Metab; 2002 Dec; 28(6 Pt 1):437-45. PubMed ID: 12522323
[TBL] [Abstract][Full Text] [Related]
8. Glimepiride pharmacokinetics in obese versus non-obese diabetic patients.
Shukla UA; Chi EM; Lehr KH
Ann Pharmacother; 2004 Jan; 38(1):30-5. PubMed ID: 14742789
[TBL] [Abstract][Full Text] [Related]
9. Promising new approaches.
Reasner CA
Diabetes Obes Metab; 1999 May; 1 Suppl 1():S41-8. PubMed ID: 11220287
[TBL] [Abstract][Full Text] [Related]
10. Leptin concentration in non-obese and obese children with type 1 diabetes mellitus.
Verrotti A; Basciani F; De Simone M; Morgese G; Chiarelli F
Biomed Pharmacother; 2000 Mar; 54(2):69-73. PubMed ID: 10759289
[TBL] [Abstract][Full Text] [Related]
11. Heterogeneity in the prevalence of risk factors for cardiovascular disease and type 2 diabetes mellitus in obese individuals: effect of differences in insulin sensitivity.
McLaughlin T; Abbasi F; Lamendola C; Reaven G
Arch Intern Med; 2007 Apr; 167(7):642-8. PubMed ID: 17420421
[TBL] [Abstract][Full Text] [Related]
12. Hepatic insulin resistance in obese non-diabetic subjects and in type 2 diabetic patients.
Paquot N; Scheen AJ; Dirlewanger M; Lefèbvre PJ; Tappy L
Obes Res; 2002 Mar; 10(3):129-34. PubMed ID: 11886934
[TBL] [Abstract][Full Text] [Related]
13. Insulin signalling in skeletal muscle of subjects with or without Type II-diabetes and first degree relatives of patients with the disease.
Meyer MM; Levin K; Grimmsmann T; Beck-Nielsen H; Klein HH
Diabetologia; 2002 Jun; 45(6):813-22. PubMed ID: 12107725
[TBL] [Abstract][Full Text] [Related]
14. [Expression of omentin in adipose tissues in obese and type 2 diabetic patients].
Cai RC; Wei L; DI JZ; Yu HY; Bao YQ; Jia WP
Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(6):381-4. PubMed ID: 19567114
[TBL] [Abstract][Full Text] [Related]
15. Acute effects of valsartan on insulin sensitivity in obese, non-hypertensive subjects with and without type 2 diabetes.
Luzio SD; Dunseath G; Owens DR
Horm Metab Res; 2002 May; 34(5):271-4. PubMed ID: 12063642
[TBL] [Abstract][Full Text] [Related]
16. Rosiglitazone is more effective than metformin in improving fasting indexes of glucose metabolism in severely obese, non-diabetic patients.
Brunani A; Caumo A; Graci S; Castagna G; Viberti G; Liuzzi A
Diabetes Obes Metab; 2008 Jun; 10(6):460-7. PubMed ID: 17394563
[TBL] [Abstract][Full Text] [Related]
17. Relationship of adiposity to subclinical atherosclerosis in obese patients with type 2 diabetes.
Hegazi RA; Sutton-Tyrrell K; Evans RW; Kuller LH; Belle S; Yamamoto M; Edmundowicz D; Kelley DE
Obes Res; 2003 Dec; 11(12):1597-605. PubMed ID: 14694226
[TBL] [Abstract][Full Text] [Related]
18. The fatty acid transporter FAT/CD36 is upregulated in subcutaneous and visceral adipose tissues in human obesity and type 2 diabetes.
Bonen A; Tandon NN; Glatz JF; Luiken JJ; Heigenhauser GJ
Int J Obes (Lond); 2006 Jun; 30(6):877-83. PubMed ID: 16418758
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus.
Petersen KR
Dan Med Bull; 2002 Feb; 49(1):43-60. PubMed ID: 11894723
[TBL] [Abstract][Full Text] [Related]
20. [Clinical and metabolic results of the normalization of body weight in obese patients with diabetes mellitus type 2].
Ponikowska I; Graczykowska-Koczorowska A
Pol Tyg Lek; 1986 Mar; 41(11):327-30. PubMed ID: 3714542
[No Abstract] [Full Text] [Related]
[Next] [New Search]
